Assessing the Future of Solid Tumor Immunotherapy

Vaccine Therapies for Cancer: Then and Now

(2021) Michael A. Morse et al.   Targeted Oncology

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

(2020) Alireza Labani-Motlagh et al.   Frontiers in Immunology

Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model

(2020) Jayanth S. Shankara Narayanan et al.   SURGERY

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

(2020) N. Lakhani et al.   ANNALS OF ONCOLOGY

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

(2020) Steven C Katz et al.   Journal for ImmunoTherapy of Cancer

Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific

(2020) Prajna Guha et al.   ONCOGENE

Current Trends in Cancer Immunotherapy

(2020) Ivan Y. Filin et al.   Biomedicines

Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis

(2019) Bin Hou et al.   DISEASE MARKERS

Cancer Vaccines

(2019) Peter J. DeMaria et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

(2019) Nataliya Volodymyrivna Uboha et al.   JOURNAL OF CLINICAL ONCOLOGY

Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview

(2019) Huiyan Cheng et al.   Frontiers in Oncology

HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases

(2019) Steven C. Katz et al.   CANCER GENE THERAPY

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients

(2019) Michael J. Duffy et al.   CLINICAL CHEMISTRY

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

Bibliometric analysis of oncolytic virus research, 2000 to 2018

(2019) Yidi Zou et al.   MEDICINE

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

(2019) Lawrence P. Andrews et al.   NATURE IMMUNOLOGY

Challenges in assessing solid tumor responses to immunotherapy

(2019) Louis F. Chai et al.   CANCER GENE THERAPY

The Intriguing History of Cancer Immunotherapy

(2019) Paula Dobosz et al.   Frontiers in Immunology

The role of STAT3 in leading the crosstalk between human cancers and the immune system

(2018) Yu Wang et al.   CANCER LETTERS

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

(2018) Ye Li et al.   Cell Stem Cell

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

(2018) Wantong Song et al.   Nature Communications

Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer

(2018) D.E. Meyers et al.   Current Oncology

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

Cytokines in clinical cancer immunotherapy

(2018) Pedro Berraondo et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells

(2018) Camille Khairallah et al.   Frontiers in Immunology

NK Cell-Based Immunotherapy in Cancer Metastasis

(2018) Seila Lorenzo-Herrero et al.   Cancers

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

(2017) Florie Bertrand et al.   Nature Communications

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

(2017) John P. Veluchamy et al.   Frontiers in Immunology

Prospects for combined use of oncolytic viruses and CAR T-cells

(2017) Adam Ajina et al.   Journal for ImmunoTherapy of Cancer

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

(2017) Riccardo Giampieri et al.   Scientific Reports

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment

(2016) Petra Kucerova et al.   ANTI-CANCER DRUGS

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

(2016) Christoph Domschke et al.   Breast Care

Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases

(2016) M Thorn et al.   CANCER GENE THERAPY

Oncolytic virus therapy: A new era of cancer treatment at dawn

(2016) Hiroshi Fukuhara et al.   CANCER SCIENCE

Reversing T-cell Dysfunction and Exhaustion in Cancer

(2016) H. M. Zarour   CLINICAL CANCER RESEARCH

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

(2015) Rachel A. Burga et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

(2015) Martha R. Neagu et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Improving drug delivery to solid tumors: Priming the tumor microenvironment

(2015) Iftikhar Ali Khawar et al.   JOURNAL OF CONTROLLED RELEASE

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

(2015) Evan J Lipson et al.   Journal of Translational Medicine

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity

(2015) David L. Hermanson et al.   Frontiers in Immunology

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

(2014) Liufu Deng et al.   IMMUNITY

Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells

(2014) Alessandro Poggi et al.   IMMUNOLOGY LETTERS

Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells

(2014) Martin Wilhelm et al.   Journal of Translational Medicine

NF-κB Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells

(2014) David J. Wang et al.   Cell Reports

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

Immunological off-target effects of standard treatments in gastrointestinal cancers

(2013) A. G. Duffy et al.   ANNALS OF ONCOLOGY

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

(2013) M. J. Besser et al.   CLINICAL CANCER RESEARCH

Live viruses to treat cancer

(2013) Oliver Donnelly et al.   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor

(2013) Drew C Deniger et al.   MOLECULAR THERAPY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia

(2012) Yuliya Pylayeva-Gupta et al.   CANCER CELL

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

Cancer and Radiation Therapy: Current Advances and Future Directions

(2012) Rajamanickam Baskar et al.   International Journal of Medical Sciences

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

(2012) Kevin J. Curran et al.   JOURNAL OF GENE MEDICINE

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells

(2011) Hitoe Torisu-Itakura et al.   JOURNAL OF IMMUNOTHERAPY

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

(2011) Orit Itzhaki et al.   JOURNAL OF IMMUNOTHERAPY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

(2011) Grazia Graziani et al.   PHARMACOLOGICAL RESEARCH

Multistage nanoparticle delivery system for deep penetration into tumor tissue

(2011) C. Wong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis

(2009) Julia Bollrath et al.   CANCER CELL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

TGFβ in Cancer

(2008) Joan Massagué   CELL

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Systemic Cancer Treatment Related Side Effects: Are We Changing the Promethean Experience With Molecularly Targeted Therapies?

(2008) Carlo De Angelis   Current Oncology

Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis

(2008) Boryana K. Popivanova et al.   JOURNAL OF CLINICAL INVESTIGATION

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE